Dexmedetomidine: therapeutic use for the termination of reentrant supraventricular tachycardia
Congenital Heart Disease,  Clinical Article

Chrysostomou C et al. – Dexmedetomidine appears to have novel antiarrhythmic properties for the acute termination of reentrant SVT. Although adenosine is very effective, dexmedetomidine may prove to possess a more favorable therapeutic profile with increased effectiveness and fewer side effects.

Methods
  • Retrospective case series.
  • Quaternary University Children's Hospital, Cardiac Intensive Care Unit.
  • Patients who received dexmedetomidine for SVT in the past 5 years.
  • None.
  • SVT episodes terminated with dexmedetomidine were compared with episodes terminated with adenosine

Results
  • Fifteen patients, median age of 10 days (6–16), were given 27 doses of dexmedetomidine, mean dose 0.7 ± 0.3 mcg/kg, for a total of 27 episodes of SVT.
  • Successful termination occurred in 26 episodes (96%) at a median time of 30 seconds (20–35).
  • Duration of sinus pause was 0.6 ± 0.2 seconds, there was one episode of hypotension and no bradycardia and sedation lasted for 34 ± 8 minutes.
  • Five patients received 27 doses of adenosine, with an overall successful cardioversion in 17 patients (63%) (P= .0017).
  • Transient bradycardia and hypotension was seen in three patients (11%), agitation in 16 patients (59%), and broncospasm in one patient.
  • Median sinus pause was 2.5 seconds (2–9) (P < .001).

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Nurse Practitioner

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Nurse Practitioner Articles

Indexed Journals in Nurse Practitioner: Journal of the American Academy of Nurse Practitioners, Holistic Nursing Practicemore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close